Читать книгу The SAGE Encyclopedia of Stem Cell Research - Группа авторов - Страница 381

Current trends in the treatment of hematologic malignancies include the use of standard chemotherapeutic regimens such as anticancer drugs. However, this approach can only be conducted as long as the patient is showing a response to the treatment. In the event that a patient does not respond to a particular drug, then there is a potential that the patient might be a good candidate for a clinical trial. Patients who are classified as being high risk are offered discussions of their options of using HSCT. The goals of HSCT may vary among patients and thus the optimal scheme for these types of malignancies is to identify a scheme that would be effective in preventing further progression of the disease without resulting in adverse reactions in the patient.

Rhea U. Vallente

Independent Scholar

See Also: Blood Adult Stem Cell: Existing or Potential Regenerative Medicine Strategies; Clinical Trials, U.S.: Graft Failure, Graft-Versus-Host Disease.